Return on Investment of HIV Care Within Universal Health Coverage in Low‐ and Middle‐Income Countries: Evidence From Morocco
The International Journal of Health Planning and Management · 2026-07 · 41 (4) · 683-691
DOI: 10.1002/hpm.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Health Planning and Management, online erschienen am 28.04.2026. Verfasst von Chakib Boukhalfa und 7 weiteren Autor:innen. Beteiligte Einrichtung: National School of Public Health, Rabat, Morocco. Hauptthemen laut MEDLINE: Universal Health Insurance, HIV Infections, Developing Countries. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Global Fund to Fight AIDS, Tuberculosis and Malaria.
Abstract (Originalsprache)
HIV is a serious disease requiring long‐term care and incurring high economic costs, particularly in low‐ and middle‐income countries (LMICs). In Morocco, since 1998, the Ministry of Health has provided free care for people living with HIV, with financial support from the Global Fund. The study assessed the return on investment of providing HIV care as part of universal health coverage (UHC) financed by national health insurance in order to reduce dependence on international aid. We measured the benefit‐cost ratio of the direct benefits and expected economic costs of HIV care under UHC between 2022 and 2025. We considered the essential HIV care package, which includes antiretroviral treatment, other medicines for some opportunistic infections, initial HIV testing, follow‐up immunovirological tests, and medical visits. The total cost of HIV care as part of UHC between 2022 and 2025 was estimated at 1,036,675,480 Moroccan Dirhams (MAD). The monetary value gained as a result of the 4136 deaths avoided was estimated at 3,732,997,634 MAD. The return on investment was therefore estimated at 3.6 ≈ 4. This return on investment could be even higher, considering the indirect and/or social benefits. The provision of care and treatment to people living with HIV as part of UHC appears to be an efficient strategy in Morocco. This finding may inform UHC efforts in other LMICs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National School of Public Health, Rabat, Morocco.
- Division of Sexually Transmitted Diseases and AIDS, Department of Epidemiology and Disease Control, Ministry of Health and Social Protection, Rabat, Morocco.
- Support Program Management Unit, Global Fund, Rabat, Morocco.
- Mohammed VI International School of Public Health, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco.
- Laboratory of Public Health, Health Economics, and Health Management, Mohammed VI University of Sciences and Health (UM6SS), Casablanca, Morocco.
- Institute for Healthcare System Analysis (IA2S), Paris, France.
ORCID-Profile: Chakib Boukhalfa, Saad Zbiri
Förderung
- Global Fund to Fight AIDS, Tuberculosis and Malaria
Zitieren
APA
Boukhalfa, C., Khoudri, I., Sakhri, N., Belbachir, K., Ghanam, M., Selma El Omari, B., Zbiri, S., & Youbi, M. (2026). Return on Investment of HIV Care Within Universal Health Coverage in Low‐ and Middle‐Income Countries: Evidence From Morocco. The International Journal of Health Planning and Management, 41(4), 683-691. https://doi.org/10.1002/hpm.70081
Vancouver
Boukhalfa C, Khoudri I, Sakhri N, Belbachir K, Ghanam M, Selma El Omari B, et al. Return on Investment of HIV Care Within Universal Health Coverage in Low‐ and Middle‐Income Countries: Evidence From Morocco. The International Journal of Health Planning and Management. 2026;41(4):683-691. doi:10.1002/hpm.70081
BibTeX
@article{Boukhalfa2026,
author = {Boukhalfa, Chakib and Khoudri, Ibtissam and Sakhri, Nourredine and Belbachir, Khadija and Ghanam, Meriem and Selma El Omari, Boutaina and Zbiri, Saad and Youbi, Mohammed},
title = {Return on Investment of HIV Care Within Universal Health Coverage in Low‐ and Middle‐Income Countries: Evidence From Morocco},
journal = {The International Journal of Health Planning and Management},
year = {2026},
volume = {41},
number = {4},
pages = {683--691},
doi = {10.1002/hpm.70081}
}
EUVIMED